Christopher Posner insider trades: Cara Therapeutics (CARA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | CARA | ↓ Sell | 583 | $4.75 | $3K | Direct | Mar 4, 2025 (4d) |
| Feb 4, 2025 | CARA | ↓ Sell | 372 | $4.72 | $2K | Direct | Feb 6, 2025 (2d) |
| Nov 4, 2024 | CARA | ↓ Sell | 3,668 | $0.29 | $1K | Direct | Nov 6, 2024 (2d) |
| Aug 1, 2024 | CARA | ↓ Sell | 4,149 | $0.35 | $1K | Direct | Aug 2, 2024 (1d) |
| May 2, 2024 | CARA | ↓ Sell | 3,936 | $0.75 | $3K | Direct | May 6, 2024 (4d) |
| Feb 29, 2024 | CARA | ↓ Sell | 5,834 | $0.89 | $5K | Direct | Mar 4, 2024 (4d) |
| Feb 8, 2024 | CARA | ↓ Sell | 35,575 | $0.53 | $19K | Direct | Feb 12, 2024 (4d) |
| Feb 1, 2024 | CARA | ↓ Sell | 4,981 | $0.55 | $3K | Direct | Feb 5, 2024 (4d) |
| Nov 2, 2023 | CARA | ↓ Sell | 3,796 | $1.22 | $5K | Direct | Nov 3, 2023 (1d) |
| Aug 3, 2023 | CARA | ↓ Sell | 4,307 | $3.07 | $13K | Direct | Aug 4, 2023 (1d) |
| May 5, 2023 | CARA | ↓ Sell | 3,869 | $4.40 | $17K | Direct | May 9, 2023 (4d) |
| Mar 3, 2023 | CARA | ↓ Sell | 5,987 | $9.71 | $58K | Direct | Mar 7, 2023 (4d) |
| Feb 2, 2023 | CARA | ↓ Sell | 4,191 | $11.80 | $49K | Direct | Feb 3, 2023 (1d) |
| Nov 16, 2022 | CARA | ↓ Sell | 14,470 | $11.13 | $161K | Direct | Nov 18, 2022 (2d) |
| Apr 4, 2022 | CARA | ↓ Sell | 2,006 | $12.67 | $25K | Direct | Apr 5, 2022 (1d) |
| Jun 7, 2021 | CARA | ↓ Sell10b5-1 | 2,304 | $13.04 | $30K | Direct | Jun 7, 2021 (0d) |
| Nov 19, 2020 | CARA | ↓ Sell | 2,000 | $15.82 | $32K | Direct | Nov 23, 2020 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Christopher Posner's insider trades
Christopher Posner is President and CEO at Cara Therapeutics (CARA). Since Nov 19, 2020, Christopher has reported no open-market purchases and 17 sales worth $427K on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (7% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CARA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.